Article
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2022
Hayashi Hidetoshi, Yonesaka Kimio, Nakamura Atsushi, Fujimoto Daichi, Azuma Koichi, Sakata Shinya, Tachihara Motoko, Ikeda Satoshi, Yokoyama Toshihide, Hataji Osamu, Yano Yukihiro, Hirano Katsuya, Daga Haruko, Okada Hideaki, Chiba Yasutaka, Sakai Kazuko, Nishio Kazuto, Yamamoto Nobuyuki, Nakagawa Kazuhiko
Abstract excerpt
INTRODUCTION: Alternation of osimertinib and afatinib is a potential approach to overcome osimertinib resistance and to allow complementation of drug efficacy without compromising safety in patients with epidermal growth factor receptor gene (EGFR)-mutated non-small cell lung cancer (NSCLC). METHODS: Treatment-naive patients with stage IV NSCLC harboring an activating EGFR mutation (L858R or exon-19 deletion)...
Topics
Join the communities discussing this publication.